AVX 001

Drug Profile

AVX 001

Alternative Names: AKH-217; AVX-001

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Avexxin
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunomodulators; Phospholipase A2 modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis

Most Recent Events

  • 28 Sep 2016 Phase-II clinical trials in Atopic dermatitis (In adolescents, In adults, In the elderly) in Denmark (Topical) (EudraCT2016-003013-96)
  • 02 Jul 2015 Avexxin completes a phase-I/II trial in Psoriasis
  • 01 May 2015 Avexxin completes a phase II trial in Plaque psoriasis in Denmark (EudraCT2014-004467-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top